{"disease":{"id":"graft-versus-host-disease","name":"graft versus host disease"},"drugs":{"marketed":[{"drug_id":"ibrutinib","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imbruvica","generic_name":"ibrutinib","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Blk","drug_class":"Kinase Inhibitor [EPC]","quality_score":74,"revenue":"3200","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells."},{"drug_id":"ruxolitinib","indication_name":"Acute graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"ruxolitinib","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"axatilimab","indication_name":"chronic graft-versus-host disease (cGVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niktimvo","generic_name":"AXATILIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Colony Stimulating Factor-1 Receptor Blocker [EPC]","quality_score":44,"revenue":null,"mechanism":"Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"imbruvica","indication_name":"Chronic graft-versus-host disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Imbruvica","company_name":"Rabin Medical Center","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mycophenolate-mofetil","indication_name":"The suppression of graft-versus-host disease in hematopoietic stem cell transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cellcept","generic_name":"MYCOPHENOLATE MOFETIL","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Inosine-5'-monophosphate dehydrogenase 2","drug_class":"Antimetabolite Immunosuppressant","quality_score":75,"revenue":null,"mechanism":"Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"belumosudil","indication_name":"Chronic graft-versus-host disease (chronic GVHD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rezurock","generic_name":"BELUMOSUDIL","company_name":"Kadmon Pharms Llc","drug_phase":"marketed","molecular_target":"Rho-associated protein kinase 1","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Rezurock works by inhibiting the Rho-associated protein kinase 1 enzyme, which plays a key role in inflammation and immune response."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Graft-Versus-Host Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":14,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00128973","title":"Evaluation of Patients With Immune Function Abnormalities","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05655546","title":"ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals","phase":"NA","overall_status":"TERMINATED","enrollment_count":2117,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":true},{"nct_id":"NCT07297914","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Bambino Gesù Hospital and Research Institute","has_results":false},{"nct_id":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06615050","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":572,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03602599","title":"Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","has_results":false},{"nct_id":"NCT06386445","title":"Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT00001529","title":"Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT04014413","title":"Safety and Efficacy of Fecal Microbiota Transplantation","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT03139604","title":"GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":439,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06910969","title":"Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03112603","title":"A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":330,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT06705062","title":"Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT05355675","title":"The Association of Microbiota Composition With cGVHD After Allo-HSCT","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT04431479","title":"Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06593834","title":"A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":286,"lead_sponsor_name":"Yamin Fan","has_results":false},{"nct_id":"NCT02386800","title":"CINC424A2X01B Rollover Protocol","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":279,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06394895","title":"Donor Neutrophil Subsets to Predict the Risk of aGVHD","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT00366145","title":"Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"Mesoblast, Inc.","has_results":false},{"nct_id":"NCT00544115","title":"Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06143891","title":"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT01521039","title":"Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease","phase":"","overall_status":"COMPLETED","enrollment_count":259,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02991846","title":"A Prospective Observational Study for Evaluating CGVHD","phase":"","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Gruppo Italiano Trapianto di Midollo Osseo","has_results":false},{"nct_id":"NCT06585774","title":"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03805789","title":"The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":222,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT05921305","title":"Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":218,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT04838704","title":"Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation","phase":"NA","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03727113","title":"Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors","phase":"","overall_status":"COMPLETED","enrollment_count":211,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT03557749","title":"Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies","phase":"","overall_status":"TERMINATED","enrollment_count":210,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06321003","title":"SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Palermo","has_results":false},{"nct_id":"NCT06294691","title":"Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":198,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT06294678","title":"Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":198,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT02959944","title":"Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Pharmacyclics LLC.","has_results":true},{"nct_id":"NCT03190733","title":"A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":192,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT00562497","title":"Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"Mesoblast, Inc.","has_results":false},{"nct_id":"NCT05149365","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06880419","title":"Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03057054","title":"Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":173,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03640481","title":"Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Kadmon, a Sanofi Company","has_results":true},{"nct_id":"NCT03204721","title":"Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis","phase":"NA","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT05263999","title":"A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":158,"lead_sponsor_name":"Equillium","has_results":false},{"nct_id":"NCT03584516","title":"GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":155,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04692376","title":"MSC for Treatment of cGVHD After Allo-HSCT","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":152,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03339297","title":"An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT03894488","title":"Clinical Evaluation of the Application of the FilmArray GI Panel in Post-HSCT Diarrhea Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Shanghai Children's Medical Center","has_results":false},{"nct_id":"NCT06026371","title":"Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT04167514","title":"Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT07047456","title":"Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT04669210","title":"PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT05621733","title":"A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}